A Phase 3 interventional study of Frexalimab and Placebo in Multiple Sclerosis, sponsored by Sanofi. Active, not recruiting at 311 sites in 27 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Multiple Sclerosis by Sanofi — 3 open to participants now, 6 under way, 4 of them phase 3. Multiple Sclerosis · Sanofi.
Among the 44 studies in Multiple Sclerosis by Sanofi, this one is the 8th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2023, is one of 18 in phase 3, and was the 40th registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →3 of the 44 studies in Multiple Sclerosis by Sanofi are open now, in 8 countries. Recruiting first, the newest first:
Sanofi · Sites in United Arab Emirates
Ages 18+
Sanofi · Sites in United States, Belgium, Brazil and 4 more countries
Ages 18–60
Sanofi
Ages 18–60
By country, each count listing its studies:
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 943 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 166 across the 41 interventional studies, 220 across the 3 observational. Of the 38 that completed or were terminated, 23 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
2 of the studies in Multiple Sclerosis by Sanofi that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141473Phase 3SanofiEfficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | 2027-05-06 |
| NCT07325292Phase 3SanofiNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | 2027-07-15 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Multiple Sclerosis by Sanofi, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to 36 months double-blind administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Frexalimab IV administration
Drug: Frexalimab · Drug: MRI contrast-enhancing agents
Matching placebo
Drug: Placebo · Drug: MRI contrast-enhancing agents
SAR441344 Solution for IV infusion
Solution for IV infusion
IV, as per respective label
Time to onset of composite confirmed disability progression (cCDP) confirmed over 6 months in the double-blind treatment period
Defined as Increase from the baseline expanded disability status scale (EDSS) score of ≥1.0 point when the baseline is \<5.5, or ≥0.5 point when the baseline is ≥5.5, OR Increase of ≥20% from the baseline time in the 9 hole peg test (9HPT),OR Increase of ≥20% from the baseline time in the timed 25 foot walk (T25FW) test
Time frame: Up to 36 months
Time to onset of composite cCDP confirmed over 3 months in the double-blind treatment period
Time frame: Up to 36 months
Time to onset of individual components of the composite, confirmed over 3-months or 6 months in the double-blind treatment period
increase from the baseline EDSS score of ≥1.0 point when the baseline is \<5.5, or ≥0.5 point when the baseline is ≥5.5
Time frame: Up to 36 months
Time to onset of confirmed disability improvement (CDI) in the double-blind treatment period
defined as decrease from the baseline EDSS score of ≥1.0 or ≥ 0.5 points when baseline is ≤5.5 or \>5.5 points, respectively, confirmed over 6 months.
Time frame: Up to 36 months
Number of new and/or enlarging T2 hyperintense lesions per year as detected by MRI
defined as the sum of the individual number of new and/or enlarging T2-hyperintense lesions at all scheduled visits starting after baseline up to the end of double-blind treatment period
Time frame: Up to 36 months
Percent change in brain volume loss as detected by MRI scans at the end of double-blind treatment period compared to Month 6
Time frame: Up to 36 months
Change in cognitive function at the end of double-blind treatment period compared to baseline as assessed by symbol digit modalities test (SDMT)
Time frame: Baseline, Up to 36 months
Change from baseline in multiple sclerosis impact scale 29 version 2 (MSIS-29v2) questionnaire scores over time in the double-blind treatment period
Time frame: Baseline, Up to 36 months
Change from baseline in patient reported outcome measurement information system (PROMIS) Fatigue multiple sclerosis (MS)-8a over time in the double-blind treatment period
Time frame: Baseline, Up to 36 months
Annualized relapse rate during the double-blind treatment period assessed by protocol defined adjudicated relapses
Time frame: Up to 36 months
Number of participants with adverse events, SAEs, AEs leading to permanent study intervention discontinuation and AE of special interests (AESIs)
Time frame: Up to 36 months
Number of participants with potentially clinically significant abnormalities (PCSAs) in laboratory tests, ECG, and vital signs during the study period
12-lead ECG (electrocardiogram) will be obtained using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTc intervals.
Time frame: Up to 36 months
Number of participants with antibody over time
Time frame: Up to 36 months
Change from baseline in serum Ig levels over time
Time frame: Up to 36 months
Change from baseline in plasma neurofilament light chain (NfL) levels over time in the double-blind treatment period
Time frame: Up to 36 months
Frexalimab plasma concentration over time in the double-blind treatment period
Time frame: Up to 36 months
Showing the first 100 of 311 sites across 27 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Dec 2023 (actual). Primary completion is estimated for Mar 2028, 50 months after the start.
Of 71 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 54. This study's planned 50 months is above that.
Counting every sponsor, half of 96 studies reached it within 42 months; a quarter within 26 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Frexalimab